Eli Lilly and Company (NYSE: LLY) can become the first biopharma company to reach the $1 trillion valuation threshold, courtesy of an under-trial orally administered GLP-1 drug, Orforglipron, as per the latest investment note from Morgan Stanley. $LLY Eli Lilly Has Upside, May Reach $1 Trillion, Says Morgan Stanley (Bloomberg) - PT raised to a Street-high $950 from $805; shares closed at $757.78 on Thursday pic.twitter.com/0LgV0KfrLv — Christian Fromhertz 🇺🇸 (@cfromhertz) February 16, 2024 To wit, Morgan Stanley's Terence Flynn sees Orforglipron's phase three trial results, due in 2025, as a key catalyst for Eli Lilly and Company, paving the […]
Read full article at https://wccftech.com/morgan-stanley-oral-glp-1-weight-loss-drug-can-propel-eli-lilly-and-company-to-a-1-trillion-valuation/
WccftechContinue reading/original-link]